Adicet Bio, Inc. (ACET): Depreciation & Amortization
$6.38M
Year ended 2025-12-31
$5.59M
Trailing 12 months to 2026-06-30
+35.3%
3-year compound annual growth
+39.1%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.38M | -1.3% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $6.47M | +6.1% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $6.10M | +136.8% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $2.58M | +67.4% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $1.54M | +25.4% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $1.23M | -1.0% | 2022-03-15, From 2020-01-01 |
| 2019-12-31 | $1.24M | +1.3% | 2021-03-12, From 2019-01-01 |
| 2018-12-31 | $1.22M | n/m | 2021-03-12, From 2018-01-01 |
| 2017-12-31 | $5.0K | n/a | 2020-03-12, From 2017-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $6.38M | -1.3% |
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $144.0K | -2.0% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $3.33M | +6.8% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $621.0K | +16.3% |
| Alto Neuroscience, Inc. (ANRO) | 2024-12-31 | $502.0K | +34.6% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $307.0K | -6.7% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $58.0K | -12.1% |
| PepGen Inc. (PEPG) | 2025-12-31 | $1.40M | -6.7% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $24.0K | -97.1% |
Compare ACET, TRVI, FHTX, LXRX side by side · Screen every company in Pharmaceutical Preparations ↗